Drug Trial Radar · NCT05506540
A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Feb 17, 2021
Primary completion
May 16, 2022
Study completion May 16, 2022
Sponsor
- Lead sponsor
- EnnovaBioIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a FIH, randomized, double- blind, placebo-controlled, dose -escalation study to investigate the safety, tolerability, PK, and PD of ENN0403 after single and multiple oral dose administration in healthy adult subjects. The study will include 2 parts which will proceed in a parallel staggered manner: Part A, a single ascending dose (SAD) study and Part B, a multiple ascending dose (MAD) study. Approximately 80 healthy adult subjects will be enrolled at a single site in Australia, in up to 6 cohorts in Part A (SAD study), including a Food Effect (FE) study, and up to 4 cohorts in Part B (MAD study). Part A is for the single dose use of IP, while Part B is once daily use for 14 consecutive days. Each cohort will include 8 subjects (6 receiving ENN0403 and 2 receiving placebo). Each subject will be enrolled in only 1 cohort and receive only one dose regimen in this study. Dosing will be escalated in a sequential fashion, contingent on a review of safety, tolerability, and available PK data of the previous dose level by a Safety Review Committee (SRC). The proposed dose levels/ dosing frequency of ENN0403 may be adjusted over the course of the whole study and cohorts may be added or removed depending on the emerging safety, tolerability, and available PK data.
Conditions
- Healthy
Interventions
ENN0403 1mgDrug
ENN0403 capsules for oral use
ENN0403 4mgDrug
ENN0403 capsules for oral use
ENN0403 10mgDrug
ENN0403 capsules for oral use
ENN0403 20mgDrug
ENN0403 capsules for oral use
ENN0403 30mgDrug
ENN0403 capsules for oral use
ENN0403 20mg (Fed)Drug
ENN0403 capsules for oral use
ENN0403 6mg QD X 14 DaysDrug
ENN0403 capsules for oral use
ENN0403 12mg QD X 14 DaysDrug
ENN0403 capsules for oral use
ENN0403 20mg QD X 14 DaysDrug
ENN0403 capsules for oral use
PlaceboDrug
Placebo capsules for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment emergent adverse events (TEAE) following ENN0403 administrationTime frame: From first dose of ENN0403 administration till 7 days after last dose of ENN0403 administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty Ltd
Adelaide, Adelaide, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.